We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > T cell immunotherapy

News List

Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel for Adults with Relapsed and Refractory Multiple Myeloma drugs.com
September 23, 2020
Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of their Biologics License Application (BLA) to the U.S.
Breakthrough immunotherapy for Chronic Hepatitis B virus infection en-cphi.cn
August 09, 2017
This study, a collaborative effort between Duke-NUS, various prestigious Singapore & German institutions and Lion TCR, provides a potential solution to control the HBV infection, potentially complete clearance of HBV virus and possibly leading to a cure f